The Association between Serum Irisin Concentration and Ischemic Stroke: From Aetiology to Clinic

Serum Irisin and Ischemic Stroke

  • Mustafa ÇALIK
  • Yildizhan Sengul
  • Zahide Mail Gürkan
  • Deniz Hintoğlu
  • Naile Fevziye Mısırlıoğlu
  • Hafize Uzun Istanbul University-Cerrahpasa
DOI: https://doi.org/10.5937/jomb0-36681
Keywords: Acute ischemic stroke, irisin, National Institutes of Health Stroke Scale, aetiology

Abstract


Aim: To investigate the relationship between irisin levels in serum and classification of subtype of acute ischemic stroke, National Institutes of Health Stroke Scale (NIHSS) and Modified Rankin Score (mRS) at the time of discharge from the hospital in Turkish patients who had their first acute ischemic stroke (AIS). Methods: Our study was initiated by recruiting 180 patients who applied to our emergency department with the diagnosis of AIS from May 2021 to November 2021. This study was designed as a prospective cross-sectional study. Results: A significant relationship was found between serum irisin levels and ischemic stroke aetiological factors (TAOST) (p=0.017). Increased serum irisin levels were detected in patients without neurological deficits with localization value than those with it (p<0.01). Serum irisin levels also have a negative correlation with High-density lipoprotein (HDL) value in ischemic stroke (r: -0.272, p<0.01).  Conclusions: High serum irisin levels found in patients with stroke attributed to small vessel disease and in patients with ischemic stroke in whom we did not find any neurological deficits with a localization value. Although the question how the irisin is involved in the course of ischemic stroke and what the clinical reflection has not been answered, the findings are a small step towards the answer.

References

1. Mathers CD, Boerma T, Ma Fat D. Global and regional causes of death. Br Med Bull. 2009;92:7-32. doi: 10.1093/bmb/ldp028. PMID: 19776034.
2. Karimi-Khouzani O., Heidarian E., Amini S. A. (2017). Anti-inflammatory and ameliorative effects of gallic acid on fluoxetine-induced oxidative stress and liver damage in rats. Pharmacol. Rep. 69, 830–835. 10.1016/j.pharep.2017.03.011.
3. Lapchak P. A., Zhang J. H. (2017). The high cost of stroke and stroke cytoprotection research. Transl. Stroke Res. 8, 307–317. 10.1007/s12975-016-0518-y.
4. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC. A PGC1-a-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–468. doi: 10.1038/nature10777.
5. Huh JY, Mougios V, Kabasakalis A, Fatouros I, Siopi A, Douroudos II. Exercise-induced irisin secretion is independent of age or fitness levels and increased irisin may directly modulate muscle metabolism through AMPK activation. J Clin Endocrinol Metab. 2014;99(11):E2154–E2161. doi: 10.1210/jc.2014-1437.
6. Ferrer-Martínez A, Ruiz-Lozano P, Chien KR. Mouse PeP: a novel peroxisomal protein linked to myoblast differentiation and development. Dev Dyn. 2002;224:154–167. doi: 10.1002/dvdy.10099.
7. Young M. F., Valaris S., Wrann C. D. (2019). A role for FNDC5/Irisin in the beneficial effects of exercise on the brain and in neurodegenerative diseases. Prog. Cardiovasc. Dis. 62, 172–178. 10.1016/j.pcad.2019.02.007.
8. Conti E., Grana D., Stefanoni G., Corsini A., Botta M., Magni P., et al. . (2019). Irisin and BDNF serum levels and behavioral disturbances in Alzheimer's disease. Neurol. Sci. 40, 1145–1150. 10.1007/s10072-019-03781-y.
9. Zhao Y. T., Wang J., Yano N., Zhang L. X., Wang H., Zhang S., et al. . (2019). Irisin promotes cardiac progenitor cell-induced myocardial repair and functional improvement in infarcted heart. J. Cell. Physiol. 234, 1671–1681. 10.1002/jcp.27037.
10. Wu H, Guo P, Jin Z, et al. Serum levels of irisin predict short-term outcomes in ischemic stroke. Cytokine. 2018; 10.1016/j.cyto.2018.02.017.
11. Li D. J., Li Y. H., Yuan H. B., Qu L. F., Wang P. (2017). The novel exercise-induced hormone irisin protects against neuronal injury via activation of the Akt and ERK1/2 signaling pathways and contributes to the neuroprotection of physical exercise in cerebral ischemia. Metabolism 68, 31–42. 10.1016/j.metabol.2016.12.003.
12. H.P. Adams Jr, B.H. Bendixen, L.J. Kappelle, J. Biller, B.B. Love, D.L. Gordon, et al., Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment, Stroke 24 (1993) 35–41.
13. T. Brott, H.P. Adams Jr, C.P. Olinger, J.R. Marler, W.G. Barsanl, J. Biller, et al., Measurements of acute cerebral infarction: a clinical examination scale, Stroke 20 (1989) 864–870.
14. Bonita RR. Modification of Rankin scale: recovery of motor function after stroke. Stroke. 1988;19:1497–1500. doi: 10.1161/01.STR.19.12.1497.
15. K.H. Park, L. Zaichenko, M. Brinkoetter, B. Thakkar, A. Sahin-Efe, K.E. Joung, et al., Circulating irisin in relation to insulin resistance and the metabolic syndrome, J. Clin. Endocrinol. Metab. 98 (2013) 4899–4907.
16. S. Mehrabian, E. Taheri, M. Karkhaneh, et al., Association of circulating irisin levels with normal weight obesity, glycemic and lipid profile, J. Diabetes Metabolic Disorders 15 (1) (2015) 17.
17. M.J. Lee, S.A. Lee, B.Y. Nam, et al., Irisin, a novel myokine is an independent predictor for sarcopenia and carotid atherosclerosis in dialysis patients, Atherosclerosis 242 (2) (2015) 476–482.
18. Emanuele E, Minoretti P, Pareja-Galeano H, Sanchis-Gomar F, Garatachea N, Lucia A. Serum irisin levels, precocious myocardial infarction, and healthy exceptional longevity. Am J Med. 2014 Sep;127(9):888-90. doi: 10.1016/j.amjmed.2014.04.025.
19. Jia J, Yu F, Wei WP, Yang P, Zhang R, Sheng Y, Shi YQ. Relationship between circulating irisin levels and overweight/obesity: A meta-analysis. World J Clin Cases. 2019 Jun 26;7(12):1444-1455. doi: 10.12998/wjcc.v7.i12.1444. PMID: 31363472; PMCID: PMC6656672.
20. Kırel B, Alataş İ.Ö., Serum Irisin Levels in Cigarette Smokers, Turk J Endocrinol Metab. 2021;25:95-101.Doi: 10.25179/tjem.2020-79650.
Published
2022/09/24
Issue
Vol. 41 No. 4 (2022): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2022 Hafize Uzun, Mustafa ÇALIK, Yildizhan Sengul , Zahide Mail Gürkan , Deniz Hintoğlu , Naile Fevziye Mısırlıoğlu

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.